RecruitingNCT07407439

Real-world Studies of CDK4/6 Inhibitors

A Real-world Study on the Treatment of HR+/HER2- Advanced Breast Cancer Patients With CDK4/6 Inhibitors and Treatment Options After Drug Resistance.

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Enrollment

245 participants

Start Date

Jun 1, 2025

Study Type

OBSERVATIONAL

Conditions

Breast Cancer

Summary

A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Age ≥ 18 years old;
Patients diagnosed with HR+/HER2- (as defined by the ASCO/CAP guidelines) advanced breast cancer who were treated in our hospital from March 2022 to March 2025;
Received CDK4/6 inhibitors (including but not limited to the four currently marketed ones: palbociclib, abemaciclib, ribociclib, and dalpiciclib) as advanced-stage treatment for at least one cycle;
Have complete medical history records, including demographic information, pathological reports, treatment records, laboratory test results, and imaging examination reports, etc.

Exclusion Criteria3

Incomplete medical history data.
Only received CDK4/6 inhibitors monotherapy.
Received CDK4/6 inhibitors as neoadjuvant/postoperative adjuvant intensification therapy.